Pipeline

Pipeline

Autifony’s pipeline includes clinical stage programmes for Fragile X and rare neurology and earlier stage programmes focused on Schizophrenia, Alzheimer’s Disease, Parkinson’s Disease, Fronto-Temporal Dementia and hearing loss

CompoundIndicationLead OptimizationPreclinical DevelopmentPhase IPhase II
AUT00206 (Kv3.1/Kv3.2)Fragile X Syndrome
AUT00201 (Kv3.1/Kv3.2)Orphan Neurology
Kv3.1/3.2 modulatorsSchizophrenia, Hearing Loss
Lysosomal ChannelParkinson’s Disease
Novel Genetically linked Ion ChannelAlzheimer's Disease Frontotemporal Dementia

Related Content

Related News

18Dec

Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders

0 Comments
Collaboration with funding of development activities gives Boehringer Ingelheim exclusive option to purchase certain Autifony assets to treat serious CNS... Read More →
10Jul

Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
18May

Autifony Therapeutics initiates recruitment into schizophrenia clinical trial for first-in-class drug

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
10Jan

Autifony Therapeutics announces positive results from Phase I study of AUT00206, a first-in-class Kv3 modulator for treatment of schizophrenia

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
09Aug

Autifony Announces Results from Completed CLARITY-1, Phase IIa Trial of AUT00063 in Age-related Hearing Loss

0 Comments
Autifony Therapeutics Limited, which is pioneering the development of novel pharmaceutical treatments for hearing disorders and other serious disorders of... Read More →

About

Autifony Therapeutics aims to develop new drugs to treat serious disorders of the central nervous system using pioneering science.

Science

Scientific publications can be found here as well as information on Voltage-gated ion channels as therapeutics targets and Kv3 ion channels.

Pipeline

Clinical stage programmes for schizophrenia and Fragile X, and earlier stage programmes focused on Hearing disorders and Alzheimer’s Disease.

Tweets

AutifonyLtd @AutifonyLtd
Autifony Therapeutic  @AutifonyLtd
Mar 08
RT @Instinctif_HLS:Great to see this exciting new collaboration between @AutifonyLtd and @Boehringer announced! https://t.co/Cx8LI319if
reply retweet favorite
Autifony Therapeutic  @AutifonyLtd
Mar 04
Autifony Therapeutics and Boehringer Ingelheim to collaborate on novel ion channel target with potential in multipl… https://t.co/KMvOWVf9o5
reply retweet favorite
Autifony Therapeutic  @AutifonyLtd
Aug 26
Autifony Therapeutics regains rights to clinical stage Kv3 programme https://t.co/rBHjjR7aC0
reply retweet favorite

Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image